{"id":"NCT05683249","sponsor":"Neurocentria, Inc.","briefTitle":"Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)","officialTitle":"Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2023-02-25","primaryCompletion":"2024-01-17","completion":"2024-01-17","firstPosted":"2023-01-13","resultsPosted":"2025-04-27","lastUpdate":"2025-06-03"},"enrollment":223,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["ADHD"],"interventions":[{"type":"DRUG","name":"NRCT-101-SR","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"NRCT-101SR","type":"EXPERIMENTAL"},{"label":"Matching Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The goal of this clinical trial is to evaluate the efficacy and safety of NRCT-101SR compared to placebo in adult patients with ADHD aged 18 years and older.","primaryOutcome":{"measure":"Change From Baseline in Permanent Product Measure of Performance (PERMP) - Number of Math Problems Answered Correctly (PERMP-C)","timeFrame":"Baseline and Week 6","effectByArm":[{"arm":"NRCT-101SR","deltaMin":21.8,"sd":2.17},{"arm":"Placebo","deltaMin":18.9,"sd":2.03}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":9,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":108},"commonTop":["Headache","Fatigue","Upper respiratory tract infection","Diarrhoea","COVID-19"]}}